Reference health
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
1 of 189 checkable references need attention · checked 2026-07-22
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
19 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1080/08035250500277101
The 188 checked references that resolve
resolves10.1001/jama.295.13.1549
Prevalence of Overweight and Obesity in the United States, 1999-2004
resolves10.1001/jama.2009.2012
Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008
resolves10.1038/sj.ijo.0801224
Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test
resolves10.1124/dmd.109.027466
Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
resolves10.1124/dmd.106.009670
Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts
resolves10.1016/j.tiv.2006.07.008
Effects of steatosis on drug-metabolizing capability of primary human hepatocytes
resolves10.1053/jhep.2003.50342
Cyp2e1 Activity Before and After Weight Loss in Morbidly Obese Subjects With Nonalcoholic Fatty Liver Disease
resolves10.1016/j.jclinane.2004.01.009
Anesthesia in the obese patient: Pharmacokinetic considerations
resolves10.1016/j.jpain.2010.10.012
Increased Clearance of Morphine in Sickle Cell Disease: Implications for Pain Management
resolves10.2165/11318100-000000000-00000
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
resolves10.1016/j.contraception.2010.04.016
Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review
resolves10.1111/j.1365-2125.2004.02157.x
What is the best size descriptor to use for pharmacokinetic studies in the obese?
resolves10.1381/096089203322190853
Hepatic Steatosis In Patients Undergoing Bariatric Surgery and its Relationship to Body Mass Index and Co-Morbidities
resolves10.1381/096089206775565122
Prevalence and Predictive Factors of Non-Alcoholic Steatohepatitis (NASH) in Morbidly Obese Patients Undergoing Bariatric Surgery
resolves10.1111/j.1365-2125.2005.02389.x
Cytochromes P450 and <i>MDR1</i> mRNA expression along the human gastrointestinal tract
resolves10.1046/j.1365-2362.2003.01154.x
Variable expression of CYP and Pgp genes in the human small intestine
resolves10.1126/science.286.5439.487
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
resolves10.3109/00498254.2010.501117
<i>In vitro</i>and<i>in vivo</i>metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys
resolves10.1208/s12248-010-9212-2
Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist
resolves10.1111/j.1365-2125.2010.03621.x
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co‐administration of ritonavir in patients with advanced cancer
resolves10.1200/JCO.2007.11.2938
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
resolves10.1038/clpt.1992.54
Significant weight reduction in obese subjects enhances carbamazepine elimination
resolves10.1097/00008571-200004000-00001
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
resolves10.2165/00003088-200746080-00005
General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of??Standard Drugs
resolves10.2165/00003088-198409020-00005
The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam
resolves10.1097/00007890-198905000-00012
THE IMPACT OF BODY WEIGHT ON CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS
resolves10.1007/s002130050376
Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m -chlorophenylpiperazine
resolves10.1111/j.1399-0012.1996.tb00467.x
Gastric bypass in morbidly obese kidney transplant recipients
resolves10.1177/0091270007306957
Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450‐Inducing Medications<sup>1</sup>
resolves10.1373/clinchem.2005.050047
Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus
resolves10.1097/00007691-200412000-00004
Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5
resolves10.1111/j.1399-0012.2007.00783.x
Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end‐stage renal disease and transplant patients: a pilot study
resolves10.1038/clpt.2010.32
Significant Increase in Systemic Exposure of Atorvastatin After Biliopancreatic Diversion With Duodenal Switch
resolves10.1038/clpt.2009.82
Significantly Altered Systemic Exposure to Atorvastatin Acid Following Gastric Bypass Surgery in Morbidly Obese Patients
resolves10.1097/00008571-199906000-00013
Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans
resolves10.1111/j.1472-8206.1998.tb00985.x
Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation
resolves10.1038/clpt.1994.150
Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity
resolves10.1213/00000539-197909000-00013
Serum Inorganic Fluoride Levels in Obese Patients during and after Enflurane Anesthesia
resolves10.1213/00000539-199311000-00025
Serum Inorganic Fluoride Levels in Mildly Obese Patients During and After Sevoflurane Anesthesia
resolves10.1213/00000539-199376060-00026
Plasma Inorganic Fluoride Levels with Sevoflurane Anesthesia in Morbidly Obese and Nonobese Patients
resolves10.1097/MPG.0b013e3181f9b3a0
Acetaminophen Pharmacokinetics in Children With Nonalcoholic Fatty Liver Disease
resolves10.1097/00008571-199810000-00007
Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2
resolves10.1111/j.1365-2125.2006.02796.x
The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
resolves10.1007/s002280050237
Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects
resolves10.1007/s002280050394
A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers
resolves10.1097/00008571-199604000-00001
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment
resolves10.1111/j.1365-2125.1997.00546.x
Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans
resolves10.1111/j.1365-2125.2011.03959.x
Altered xanthine oxidase and N‐acetyltransferase activity in obese children
resolves10.1007/BF00606637
The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers
resolves10.1002/jps.2600681106
Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol
resolves10.1007/s00228-009-0736-2
The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
resolves10.1097/00007691-199602000-00002
The Effects of Obesity on the Pharmacokinetics and Pharmacodynamics of Glipizide in Patients with Non-Insulin-Dependent Diabetes Mellitus
resolves10.1016/j.clpt.2004.04.006
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms*1
resolves10.1124/dmd.106.010926
CYP2C9 Inhibition: Impact of Probe Selection and Pharmacogenetics on in Vitro Inhibition Profiles
resolves10.2174/092986711794480131
Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development
resolves10.1038/clpt.1989.40
Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype
resolves10.1002/jps.2600710827
Prolongation of Drug Half-Life due to Obesity: Studies of Desmethyldiazepam (Clorazepate)
resolves10.1517/17425255.2.6.895
Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics
resolves10.2165/00003088-198611030-00004
Pharmacokinetic Drug Interactions of Commonly Used Anticancer Drugs
resolves10.1097/00007691-199101000-00004
Fat Body Mass and Pharmacokinetics of Oral 6-Mercaptopurine in Children with Acute Lymphoblastic Leukemia
resolves10.1124/dmd.109.029769
In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3
resolves10.1128/AAC.01765-10
Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults
resolves10.1016/S0026-895X(25)13456-1
Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol.
resolves10.1046/j.1365-2125.2003.01868.x
The effect of ethinyloestradiol and levonorgestrel on the CYP2C19‐mediated metabolism of omeprazole in healthy female subjects
resolves10.1021/tx970217f
Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes
resolves10.1016/j.contraception.2010.01.016
Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women
resolves10.1016/0010-7824(90)90093-B
Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids
resolves10.1016/S0090-9556(24)15077-5
A Significant Role of Human Cytochrome P450 2C8 in Amiodarone N-Deethylation: An Approach to Predict the Contribution with Relative Activity Factor
resolves10.1111/j.1365-2710.2008.00987.x
Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis
resolves10.1038/bjc.1998.295
Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo
resolves10.1007/BF00692355
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution
resolves10.1016/S0009-9236(96)90001-6
Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*
resolves10.1007/BF00193706
Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism
resolves10.1007/BF00265912
Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers
resolves10.1016/j.bcp.2009.08.003
Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide
resolves10.1007/BF00315518
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics
resolves10.1007/s00280-004-0900-4
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma
resolves10.1016/j.ejca.2003.12.026
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
resolves10.1007/s00280-008-0854-z
Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study
resolves10.1016/j.pharmthera.2004.10.013
UDP-glucuronosyltransferases and clinical drug-drug interactions
resolves10.1046/j.1365-2265.1999.00709.x
Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT–PCR method
resolves10.1021/tx050317i
Kinetics of Acetaminophen Glucuronidation by UDP-Glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential Implications in Acetaminophen−Induced Hepatotoxicity
resolves10.1124/dmd.31.11.1409
METABOLISM AND DISPOSITION OF NOVEL DES-FLUORO QUINOLONE GARENOXACIN IN EXPERIMENTAL ANIMALS AND AN INTERSPECIES SCALING OF PHARMACOKINETIC PARAMETERS
resolves10.1128/AAC.48.12.4766-4777.2004
Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections
resolves10.1124/dmd.30.11.1257
Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9
resolves10.1016/j.clpt.2005.02.006
Effect of the genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers
resolves10.1016/S0009-9236(97)90131-4
Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism*
resolves10.1016/S0090-9556(25)07498-7
Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.
resolves10.1016/j.bbmt.2011.01.013
Busulfan Dosing in Children with BMIs ≥85% Undergoing HSCT: A New Optimal Strategy
resolves10.1007/s00280-005-0029-0
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
resolves10.1182/blood.V93.12.4436
The Impact of Obesity and Disease on Busulfan Oral Clearance in Adults
resolves10.1007/s00228-006-0130-2
Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver
resolves10.2165/11592890-000000000-00000
Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients
resolves10.1093/bja/aeq195
Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model
resolves10.1097/00000542-199512000-00010
Linearity of Pharmacokinetics and Model Estimation of Sufentanil
resolves10.1016/S0090-9556(25)08435-1
Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
resolves10.1002/bdd.357
Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects
resolves10.1046/j.1365-2125.1997.00609.x
Pharmacokinetics of β‐adrenoceptor blockers in obese and normal volunteers
resolves10.1002/j.1552-4604.1987.tb05582.x
Comparative Pharmacokinetics of Intravenous Propranolol in Obese and Normal Volunteers
resolves10.1111/j.1365-2125.1986.tb02837.x
A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
resolves10.2165/00003088-198611060-00002
Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem
resolves10.1097/00005344-198811020-00013
Verapamil Pharmacodynamics and Disposition in Obese Hypertensive Patients
resolves10.1093/bja/82.6.900
Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro
resolves10.1097/00000542-200409000-00008
Accuracy of Pharmacokinetic Models for Predicting Plasma Fentanyl Concentrations in Lean and Obese Surgical Patients
resolves10.1046/j.1472-8206.2002.00108.x
MEGX disposition in critically‐ill trauma patients: subsequent assessments during the first week following trauma
resolves10.1038/clpt.1981.16
Effect of cardiopulmonary bypass on fentanyl distribution and elimination
resolves10.1007/s11095-004-1190-6
Altered Pharmacokinetics of Paclitaxel in Experimental Hepatic or Renal Failure
resolves10.1053/j.ackd.2010.05.010
Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing
resolves10.1007/s00431-004-1546-2
Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion
resolves10.1681/ASN.V1261211
Functional and Structural Changes in the Kidney in the Early Stages of Obesity
resolves10.1128/AAC.00059-07
Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin
resolves10.1177/0091270004269562
The Pharmacokinetics of Daptomycin in Moderately Obese, Morbidly Obese, and Matched Nonobese Subjects
resolves10.1007/s00280-008-0856-x
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
resolves10.1158/1078-0432.CCR-09-0017
A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients
resolves10.1111/j.1365-2125.2009.03518.x
Modelling the occurrence and severity of enoxaparin‐induced bleeding and bruising events
resolves10.1097/00004836-198312001-00008
Comparative Pharmacodynamics and Pharmacokinetics of Cimetidine and Ranitidine
resolves10.1016/0006-2952(82)90108-3
The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum II) and its modification by furosemide and probenecid
resolves10.1016/S0022-3565(24)37236-2
Probenecid Alters Topotecan Systemic and Renal Disposition by Inhibiting Renal Tubular Secretion
resolves10.1016/0002-8703(81)90100-9
Digoxin disposition in obesity: Clinical pharmacokinetic investigation
resolves10.1093/ndt/gfn379
Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption
The 19 references without a DOI — listed, not checked
no DOI — not checkedR10-1-20120410
no DOI — not checkedR29-1-20120410
no DOI — not checkedR33-1-20120410
no DOI — not checkedR35-1-20120410
no DOI — not checkedR57-1-20120410
no DOI — not checkedR61-1-20120410
no DOI — not checkedR86-1-20120410
no DOI — not checkedR93-1-20120410
no DOI — not checkedR96-1-20120410
no DOI — not checkedR146-1-20120410
no DOI — not checkedR154-1-20120410
no DOI — not checkedR159-1-20120410
no DOI — not checkedR160-1-20120410
no DOI — not checkedR162-1-20120410
no DOI — not checkedR194-1-20120410
no DOI — not checkedR197-1-20120410
no DOI — not checkedR200-1-20120410
no DOI — not checkedR202-1-20120410
no DOI — not checkedR205-1-20120410
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.2165/11599410-000000000-00000"><img src="https://citestamp.com/citestamped/10.2165/11599410-000000000-00000/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.2165/11599410-000000000-00000)